Wegovy vs Zepbound: Which Weight-Loss Drug Works Better?

What Are Wegovy and Zepbound?

Wegovy is semaglutide 2.4 mg delivered as a subcutaneous injection once weekly. Zepbound is tirzepatide, also a weekly subcutaneous injection, available in doses from 2.5 mg up to 15 mg. Both carry FDA approval specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher plus at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Semaglutide selectively activates the glucagon-like peptide-1 (GLP-1) receptor, slowing gastric emptying and reducing appetite signals in the hypothalamus. Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. That dual action appears to produce additive appetite suppression and a greater increase in energy expenditure, which likely explains why Zepbound's weight-loss numbers are consistently higher across trials [1][2].

Ozempic (semaglutide 0.5 to 2 mg) and Mounjaro (tirzepatide 2.5 to 15 mg) share the same active ingredients as their respective weight-loss siblings but carry FDA approval only for type 2 diabetes. Prescribing Ozempic or Mounjaro for weight loss without a diabetes diagnosis is off-label use.

Head-to-Head Weight-Loss Outcomes

No large, fully published randomized controlled trial has directly compared Wegovy and Zepbound in the same study. The comparison currently rests on parallel-trial data.

STEP-1 enrolled 1,961 adults without diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% versus 2.4% with placebo (P<0.001). About 86% of participants lost at least 5% of body weight [1].

SURMOUNT-1 enrolled 2,539 adults without diabetes. At 72 weeks, the highest dose group (tirzepatide 15 mg) lost a mean of 22.5% of body weight, and even the 5 mg group lost 15.0%. The 10 mg and 15 mg doses showed roughly 20% and 22% losses, respectively (P<0.001 for all doses vs. placebo) [2].

A 2023 indirect comparison published in Obesity modeled these two trials and estimated tirzepatide's advantage at approximately 5, 7 percentage points of body-weight reduction after adjustment for trial-design differences [3]. That translates to a meaningful clinical gap. For a 220-pound person, 5 percentage points means about 11 additional pounds lost.

SURMOUNT-3 tested tirzepatide after an intensive 12-week lifestyle run-in. Participants who had already lost a mean of 6.9% of body weight through diet and exercise went on to lose an additional 18.4% with tirzepatide versus 2.5% with placebo over 72 weeks [4]. This underscores the additive effect of combining medication with structured lifestyle support.

STEP-5 followed semaglutide participants for 104 weeks. The 14.8% mean weight loss seen at 68 weeks was sustained at 15.2% at 2 years, showing that the benefit does not erode significantly with continued use [5].

Mechanisms: Why the Numbers Differ

Semaglutide works through one receptor pathway. GLP-1 receptor activation reduces appetite, slows gastric emptying, and increases satiety signaling from the gut to the brain. The result is reduced calorie intake, typically around 300, 500 fewer kcal per day in clinical studies.

Tirzepatide adds GIP receptor activation on top of that. GIP receptors are found in adipose tissue, and their activation may directly reduce fat storage while also amplifying the brain's satiety response. A preclinical study in Nature Metabolism showed that tirzepatide's GIP component acts on the central nervous system to further suppress food intake beyond what GLP-1 agonism alone achieves [6]. The clinical result is a steeper dose-response curve and a higher ceiling for weight loss.

Neither drug burns fat through a stimulant mechanism. They do not raise heart rate or blood pressure the way phentermine does. Phentermine is a sympathomimetic amine that suppresses appetite via catecholamine release. In a short-term comparison, phentermine 37.5 mg produces roughly 5 to 7% weight loss over 12 weeks but lacks long-term cardiovascular-outcomes data and carries Schedule IV controlled-substance classification.

Cardiovascular Outcomes

The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean of 39.8 months (HR 0.80; 95% CI 0.72, 0.90; P<0.001) [7]. This outcome led the FDA to expand Wegovy's label in March 2024 to include reducing cardiovascular events in high-risk patients.

Tirzepatide's cardiovascular outcomes trial, SURMOUNT-MMO, was ongoing as of early 2025 with results expected in 2026. No equivalent CV label expansion exists for Zepbound yet.

The American Association of Clinical Endocrinology (AACE) obesity guidelines state: "Pharmacotherapy for obesity should be considered as part of a comprehensive treatment plan that includes lifestyle modification for patients with a BMI of 30 or higher, or 27 or higher with comorbidities." [8] The SELECT data push semaglutide ahead specifically for patients with prior MI, stroke, or established atherosclerotic cardiovascular disease.

Dosing and Titration

Both drugs use a step-up titration to reduce gastrointestinal side effects.

Wegovy titration schedule (per FDA label [9]):

• Weeks 1, 4: 0.25 mg weekly
• Weeks 5, 8: 0.5 mg weekly
• Weeks 9, 12: 1.0 mg weekly
• Weeks 13, 16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Zepbound titration schedule (per FDA label [10]):

• Weeks 1, 4: 2.5 mg weekly
• Weeks 5, 8: 5 mg weekly (first maintenance option)
• Every 4 weeks thereafter, escalate by 2.5 mg increments as tolerated
• Maximum dose: 15 mg weekly

Wegovy's titration takes 16 weeks to reach full dose. Zepbound can reach its minimum effective maintenance dose (5 mg) in just 8 weeks, though most of the additional weight loss in SURMOUNT-1 came from higher doses reached over 20 or more weeks.

If a dose escalation causes intolerable nausea, both labels permit staying at the lower dose for an additional 4 weeks before re-attempting the increase.

Side Effects and Tolerability

The side-effect profiles overlap substantially because both drugs slow gastric motility through GLP-1 receptor activation.

Most common adverse events (both drugs, from key trials):

• Nausea: 44% (Wegovy, STEP-1) vs. 31 to 39% (Zepbound, SURMOUNT-1, dose-dependent)
• Diarrhea: 30% vs. 20 to 23%
• Vomiting: 24% vs. 15 to 23%
• Constipation: 24% vs. 17 to 22%

Discontinuation due to GI events occurred in 4.5% of semaglutide participants in STEP-1 [1] and 4.3 to 6.2% of tirzepatide participants across doses in SURMOUNT-1 [2]. The rates are clinically similar.

Rare but serious risks shared by both drugs include:

• Pancreatitis. Both labels carry a warning. Incidence in trials was under 1% but prescribers should assess personal or family history of pancreatitis before initiating either drug.
• Thyroid C-cell tumors. Rodent studies showed dose-dependent C-cell hyperplasia with both semaglutide and tirzepatide. Neither drug is approved for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Gallbladder disease. Rapid weight loss increases gallstone risk. Cholelithiasis occurred in 2.5% of semaglutide participants vs. 1.2% placebo in STEP-1 [1].
• Gastroparesis-like symptoms. Extended gastric emptying can, in rare cases, progress to gastroparesis. The FDA added a warning for this in 2023.

Tirzepatide showed no higher rate of serious adverse events in SURMOUNT-1 than semaglutide showed in STEP-1, despite producing greater weight loss. That is a clinically meaningful point: more weight-loss benefit does not appear to come at the cost of more serious harm [2].

Who Is Each Drug Best Suited For?

Choosing between Wegovy and Zepbound depends on several clinical variables.

Patients who may prefer Wegovy:

• Established cardiovascular disease (prior MI, stroke, atherosclerosis). The SELECT data provide a specific mortality-relevant reason to choose semaglutide [7].
• Longer track record. Semaglutide in various formulations has been studied since roughly 2016 and the obesity-dose data now extend to 2 years in STEP-5 [5].
• Diabetes comorbidity with preference to stay on-label. Ozempic (semaglutide 1 to 2 mg) for glycemic control and Wegovy (semaglutide 2.4 mg) for weight are the same molecule, making transitions simple.

Patients who may prefer Zepbound:

• Maximum weight-loss goal. SURMOUNT-1's 22.5% mean loss at 15 mg exceeds any dose in the semaglutide program. For a 300-pound patient, that means a potential mean loss of 67 pounds versus 45 pounds.
• Type 2 diabetes. SURMOUNT-2 enrolled adults with type 2 diabetes. Tirzepatide 15 mg produced 13.4% weight loss vs. 3.3% placebo, and A1C fell by 2.1 percentage points at that dose (P<0.001) [11]. STEP-2 showed semaglutide 2.4 mg produced 9.6% weight loss in T2D patients [12]. The glycemic benefit of tirzepatide is larger in head-to-head diabetes trials (SURPASS program).
• Preference for reaching a meaningful maintenance dose faster (8 weeks to 5 mg vs. 16 weeks to 2.4 mg).

The HealthRX Clinical Selection Framework for Wegovy vs. Zepbound:

| Clinical variable | Favor Wegovy | Favor Zepbound | |---|---|---| | Established CVD (prior MI/stroke) | Yes (SELECT outcome data) | No CV outcomes trial yet | | Maximum weight-loss priority | Secondary | Primary | | Type 2 diabetes | Effective (STEP-2) | Larger A1C/weight benefit (SURMOUNT-2) | | Tolerability concern (GI) | Titration over 16 weeks | Similar GI rate; reach 5 mg in 8 weeks | | Insurance/prior auth | Varies; often similar | Varies; often similar | | Cardiovascular event history | Strong indication | Off-label for CV reduction |

Neither drug is appropriate as monotherapy without dietary change. STEP-3, which combined semaglutide 2.4 mg with intensive behavioral therapy (62 sessions over 68 weeks), produced 16.0% mean weight loss compared with 13.7% for semaglutide plus standard care. That 2.3-percentage-point difference at 68 weeks shows that behavioral support adds measurably to pharmacotherapy, even with a highly effective drug [13].

What Happens When You Stop?

SURMOUNT-4 randomized participants who had lost a mean of 20.9% of body weight on tirzepatide to either continue tirzepatide or switch to placebo. By week 88, the withdrawal group regained 14.8 percentage points of body weight while the continuation group lost an additional 5.5%. At the end of the trial the gap between groups was 20.3 percentage points [14]. Obesity behaves as a chronic condition, and the drug's effect appears dependent on continued use.

Semaglutide shows a similar pattern. A weight-regain study published in Diabetes, Obesity and Metabolism showed that participants who stopped semaglutide regained about two-thirds of their lost weight within 1 year [15]. The clinical implication is that both drugs require indefinite use or transition to another maintenance strategy to sustain results.

Cost, Insurance, and Access

Both drugs list at approximately USD 1,300, 1,400 per month without coverage. The Novo Nordisk savings card for Wegovy reduces cost to as low as USD 650 per month for commercially insured patients. Eli Lilly's savings program for Zepbound can bring cost down to USD 550 per month for eligible commercially insured patients.

Medicare Part D was prohibited from covering weight-loss drugs until the Treat and Reduce Obesity Act was passed. The situation as of early 2025 remains in flux; coverage varies by plan. Medicaid coverage differs by state.

Compounded semaglutide and tirzepatide flooded the market when FDA placed both active ingredients on the drug shortage list. The FDA removed semaglutide from the shortage list in early 2025 and tirzepatide in late 2024. Compounded versions from 503B outsourcing facilities remain a gray area; they are not FDA-approved and potency, sterility, and safety cannot be guaranteed through the same regulatory pathway as the branded products.

GLP-1 Drugs vs. Phentermine

Phentermine (alone or combined with topiramate as Qsymia) costs roughly USD 30, 60 per month without insurance, making it far more accessible than either GLP-1 drug. A 12-week trial of phentermine/topiramate ER (15 mg/92 mg) produced 10.9% weight loss at 56 weeks in the CONQUER trial. That number sits below STEP-1 and well below SURMOUNT-1.

Phentermine raises heart rate and blood pressure, making it unsuitable for patients with cardiovascular disease, uncontrolled hypertension, or hyperthyroidism. The maximum FDA-approved duration is traditionally cited as 12 weeks, though some guidelines support longer use under close supervision. GLP-1 receptor agonists have no such duration limit and carry demonstrated CV benefit at the semaglutide dose.

For patients who cannot afford Wegovy or Zepbound and lack cardiovascular contraindications, phentermine/topiramate ER remains a reasonable bridge, but the weight-loss ceiling is lower and the risk profile differs.

Practical Injection and Storage Notes

Both drugs come as prefilled autoinjector pens for subcutaneous injection in the abdomen, thigh, or upper arm. Injection sites should be rotated weekly.

Wegovy pens: store in the refrigerator at 36, 46°F. Each pen can be kept at room temperature (below 77°F) for up to 28 days. One pen per dose, no reuse.

Zepbound pens: same refrigeration requirement. Once removed from the refrigerator, usable at room temperature below 86°F for up to 21 days.

Patients commonly ask whether they can inject on different days of the week. Both labels permit shifting the injection day by up to 3 days as long as the next injection is at least 3 days after the previous one.

Drug Interactions and Contraindications

Neither drug should be started within 5 half-lives of the other. Because both have roughly 1-week half-lives, switching from one to the other typically requires no washout beyond the natural 7-day dosing interval.

Oral medications with narrow therapeutic windows (warfarin, cyclosporine, levothyroxine, certain antiepileptics) may be affected by delayed gastric emptying. Patients on these drugs need closer monitoring of drug levels after starting either GLP-1 agent.

Both drugs are contraindicated in pregnancy. Women of childbearing age should use effective contraception and discontinue the drug at least 2 months before attempting conception per current prescribing guidance.

Dr. Ania Jastreboff, lead investigator of SURMOUNT-1, noted in the New England Journal of Medicine publication: "The magnitude of weight reduction achieved with tirzepatide in this trial, including the proportion of participants who had a loss of at least 25% of body weight, makes it comparable to that observed with bariatric surgery in some series." [2] That comparison to surgery, even if imperfect, marks a clear shift in what pharmacotherapy can accomplish.

The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity recommends GLP-1 receptor agonists as first-line agents for pharmacotherapy of obesity, with the caveat that patient-specific factors including comorbidities, tolerability, and access should drive final drug selection [16].

Monitoring After Starting Either Drug

Both drugs require a baseline assessment and periodic follow-up. A reasonable monitoring schedule includes:

• Baseline: BMI, blood pressure, fasting glucose, HbA1c (if diabetes risk present), lipid panel, kidney function, thyroid history review.
• 4 weeks: Tolerability check, dose escalation decision.
• 12 weeks: Weight, blood pressure, glucose. If less than 5% weight loss at 12 weeks on a stable dose, the AACE guidelines suggest reassessing adherence, diet, and whether the dose needs adjustment [8].
• Every 3 to 6 months: Weight, blood pressure, metabolic panel. Gallbladder symptoms review.
• Annually: Lipids, HbA1c, kidney function.

A 5% weight loss at 12 to 16 weeks on a therapeutic dose is a widely used clinical benchmark for early response. Patients who do not meet it are unlikely to achieve the 15 to 22% outcomes seen in trials and may warrant dose escalation, a different drug, or adjunct behavioral therapy.

In SURMOUNT-1 to 57% of participants on tirzepatide 15 mg lost at least 20% of body weight and 36.2% lost at least 25% [2]. Those are the responder rates a prescriber can discuss with patients at treatment initiation to set realistic expectations.